Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecules, Large Molecules), By Product Type (Sterile, Non-sterile), By End-use, By Region, And Segment Forecasts 2023 - 2030

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecules, Large Molecules), By Product Type (Sterile, Non-sterile), By End-use, By Region, And Segment Forecasts 2023 - 2030

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Growth & Trends

The Europe fill finish pharmaceutical contract manufacturing market size is expected to reach USD 3.5 billion by 2030, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc. The market is driven by factors such as the increasing demand for sterile injectable drugs, the rising prevalence of chronic diseases, and the growing focus on cost containment and efficiency by pharmaceutical companies. Additionally, advancements in technology and the increasing use of contract manufacturing by pharmaceutical companies are expected to drive market growth.

The Europe fill finish pharmaceutical contract manufacturing market is also characterized by a number of trends, such as the growing importance of regulatory compliance, the increasing use of single-use technology, and the rising adoption of advanced analytical and quality control systems. Additionally, there is a growing trend towards the use of contract manufacturing by small and mid-sized pharmaceutical companies, as well as by virtual biotech companies.

Germany dominated the market in 2022 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The COVID-19 pandemic has had a significant impact, and one of the major impacts of the pandemic on the fill-finish contract manufacturing market in Europe has been an increased demand for COVID-19 vaccines and therapies. This has aided in increasing the demand for CMOs in the market since the fill-finish process requires advanced technology; thus, to reduce the cost, many Pharma and Biotech companies are more focused on outsourcing the fill-finish process, thereby boosting the overall market growth.

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Report Highlights

• On the basis of product type, Sterile accounted for the largest revenue share of 52.2% in 2022. The rise of the sterile product category is being driven by the rising demand for biologics and biosimilars, as these goods need to be manufactured using sterile techniques in order to be safe and effective
• Based on the Molecule type, the small molecule segment dominated the market in 2022 with the largest share of 61.9% in 2022 and is anticipated to show lucrative growth over the forecast period
• Based on the End-use segment, the biopharmaceutical segment dominated the market and accounted for the largest revenue share of 54.9% in 2022. The increasing demand for biologics and biosimilars is driving the growth of the biopharmaceutical end-use segment. Due to the market for biologics and biosimilars experiencing rapid expansion, biopharmaceutical companies are the main consumers of fill-finish contract manufacturing services
• Germany dominated the Europe fill-finish pharmaceutical contract manufacturing market with a revenue share of over 22.7% in 2022, as well as expected to register the fastest rate with a CAGR of 6.5% over the forecast period. Germany's central location in Europe and well-developed transportation infrastructure make it an ideal location for pharmaceutical companies looking to distribute their products throughout Europe

Please note The report will be delivered in 3-8 business days upon order notification.